Patient treatment preferences in unresectable/metastatic BRAF-mutated melanoma: a qualitative study

Patient treatment preferences in unresectable/metastatic BRAF-mutated melanoma: a qualitative study

Saved in:

Bibliographic Details
Main Authors:	T. Amaral, A. Mühlbacher, V. Aznar de Carrillo, S. Matos, A. Longeaud, E. Barbas
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001745
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable <i>BRAF</i> V600-mutated metastatic melanoma in Russia
by: N. A. Avxentyev, et al.
Published: (2023-11-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
by: Yu. S. Shakh-Paronyants, et al.
Published: (2023-03-01)

Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma
by: S. K. Zyryanov, et al.
Published: (2024-02-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024-11-01)

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
by: Felipe Ades, et al.
Published: (2012-01-01)

The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma
by: L. Mortier, et al.
Published: (2024-01-01)

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01)

A Melanosis Patient with Primary Unknown Metastatic Melanoma: Successful Treatment with BRAF/MEK Inhibitors
by: Faruk Tas
Published: (2025-04-01)

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022-07-01)

Identifying a wide range of mutations in the <i>BRAF</i> gene for prescribing targeted drugs for melanoma treatment
by: A. N. Toropovskiy, et al.
Published: (2023-03-01)

Predicting BRAF Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis
by: Oleksandr Dudin, et al.
Published: (2024-01-01)

Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma
by: Riyue Bao, et al.
Published: (2025-02-01)

The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma
by: M. B. Aksenenko, et al.
Published: (2019-10-01)

A post-marketing surveillance study of dabrafenib and trametinib combination in Japanese patients with unresectable advanced or recurrent BRAF-mutated NSCLC
by: Tomoaki Kaizuka, et al.
Published: (2025-07-01)

Braf-Mutant Melanomas: Biology and Therapy
by: Elvira Pelosi, et al.
Published: (2024-12-01)

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation
by: Julia Forschner, et al.
Published: (2025-08-01)

The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.
by: Gholamreza Safaee Ardekani, et al.
Published: (2012-01-01)

Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma
by: Mora Guardamagna, et al.
Published: (2025-07-01)

Pharmacokinetic Evaluation of [C]CEP-32496 in Nude Mice Bearing BRAF Mutation-Induced Melanomas
by: Cuiping Jiang MMSc, et al.
Published: (2018-09-01)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
by: Caitlyn N. Myrdal, et al.
Published: (2020-01-01)

Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry.
by: Ana Claudia Urvanegia, et al.
Published: (2017-01-01)

A compilation of 13 patients with metastatic colorectal cancer and concomitant BRAF and RAS family mutations
by: Jigisha Srivastav, et al.
Published: (2025-08-01)

Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case
by: V. E. Askarov, et al.
Published: (2025-07-01)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
by: Ryan J. Sullivan, et al.
Published: (2011-01-01)

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors
by: Julie Delyon, et al.
Published: (2024-11-01)

KIT, NRAS and BRAF mutations in head and neck (upper aerodigestive tract) mucosal melanoma (a study of 21 cases)
by: A. V. Ignatova, et al.
Published: (2017-04-01)

Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆
by: G.K. In, et al.
Published: (2024-12-01)

DETECTION OF SOMATIC MUTATIONS IN THE BRAF GENE BY PYROSEQUENCING
by: O. P. Dribnokhodova, et al.
Published: (2021-10-01)

Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis
by: Mathilde Berger, et al.
Published: (2020-04-01)

Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study
by: Clara Mayo de las Casas, et al.
Published: (2025-01-01)

Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report
by: Carlotta Bertolina, et al.
Published: (2025-06-01)

Melanoma genomics – will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2024-09-01)

Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
by: Josué Ballesteros-Álvarez, et al.
Published: (2024-10-01)

Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma
by: Jiri Polivka, et al.
Published: (2024-10-01)

The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis
by: Mauricio Fernando Silva Almeida Ribeiro, et al.
Published: (2022-10-01)

Isolated chemohyperthermal perfusion of the liver with melphalan in the treatment of unresectable liver metastases with uveal melanoma
by: A. D. Kaprin, et al.
Published: (2021-12-01)

Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility
by: Jonas K. Oddershede, et al.
Published: (2025-04-01)

THE ROLE OF BRAF MUTATION STATUS IN SURGICAL TREATMENT OF WELL-DIFFERENTIATED THYROID CANCER
by: A. P. Polyakov, et al.
Published: (2017-04-01)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01)

Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma
by: Anusha Vittal, et al.
Published: (2017-01-01)